Gold Down Over 2%; 3M Profit Beats Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2024
0mins
Source: Benzinga
- Stock Market Performance: U.S. stocks traded lower with the Dow Jones falling around 1% on Tuesday, while the NASDAQ and S&P 500 also experienced declines.
- Top Headline: 3M Company reported better-than-expected first-quarter results with net sales of $8.00 billion and adjusted EPS of $2.39.
- Equities Trading: Akili, Inc., GeneDx Holdings Corp., and Global Mofy Metaverse Limited saw significant increases in their share prices, while Chegg, Inc., NRx Pharmaceuticals, Inc., and Medifast, Inc. experienced declines.
- Commodities: Oil traded down to $82.08, gold fell to $2,306.60, silver dropped to $26.645, and copper decreased to $4.5590.
- Eurozone and Asia Pacific Markets: European shares were lower, and Asian markets closed mixed with various economic indicators reported for different countries.
Analyst Views on WGS
Wall Street analysts forecast WGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WGS is 155.24 USD with a low forecast of 118.42 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 109.280
Low
118.42
Averages
155.24
High
170.00
Current: 109.280
Low
118.42
Averages
155.24
High
170.00
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
